Replies to post #106375 on Biotech Values

[jq1234]

It looks like a new version of thigh master :-)

[mcbio]

Re: IMGN/T-DM1

This cartoon of IMGN’s T-DMI comes from a recent Roche webcast.
I found it noteworthy because of the ‘3.5:1’ notation in the caption.

Can you clarify what you find noteworthy about that? I'm trying to understand the context of the 3.5:1.

Separately, I will say, after listening to the Roche CC last night for any additional Danoprevir guidance in Q&A (there was no additional guidance or mention of the drug beyond that quote from the Seeking Alpha transcript), you can tell how important T-DM1 is to Roche just on how often the drug was cited by Roche during their planned remarks. That has to bode well for IMGN. I should go back and listen to the call as I do have IMGN on my watch list. I know there was some discussion by Roche about their strong expectation of having premium pricing for T-DM1 compared to Herceptin worldwide. There was also a fairly critical question from one analyst questioning some type of safety aspect of T-DM1 (and possibly efficacy as well) being worse compared to the control arm, but Roche seemed to be able to counter the question fairly well. I should go back and listen as I was only partially paying attention to that specific Q&A.